Edurant (rilpivirine) / J&J 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12345678910111213»
  • ||||||||||  Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD)
    PK/PD data, Journal:  In Silico Pharmacokinetics Evaluation of Forgiveness for Doravirine and Rilpivirine. (Pubmed Central) -  May 9, 2024   
    These findings suggest that treatment with DOR may offer a more forgiving therapeutic profile than RLP, given the larger proportion of patients achieving effective drug exposure with DOR. However, it is important to acknowledge a significant limitation of this study, namely, the assumption that drug concentration is a perfect surrogate for drug effectiveness.
  • ||||||||||  Prezista (darunavir) / J&J, Edurant (rilpivirine) / J&J, Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Daiichi Sankyo
    Review, Journal:  Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas. (Pubmed Central) -  Apr 27, 2024   
    For those intolerant or not meeting therapeutic goals, the addition of ezetimibe, PCSK9, bempedoic acid, fibrates, or fish oils should also be considered. This review summarizes the current literature on the multifactorial etiology and intricate pathophysiology of hyperlipidemia in PLHIV, with an emphasis on the role of different HAART agents, while also providing valuable insights into potential switching strategies and therapeutic options.
  • ||||||||||  Edurant (rilpivirine) / J&J, Isentress (raltegravir) / Merck (MSD), Vemlidy (tenofovir alafenamide) / Gilead
    Journal:  Plasma concentrations of antiretroviral drugs in a successful 4-days-a-week maintenance treatment strategy in HIV-1 patients (ANRS 170-Quatuor trial). (Pubmed Central) -  Apr 24, 2024   
    This review summarizes the current literature on the multifactorial etiology and intricate pathophysiology of hyperlipidemia in PLHIV, with an emphasis on the role of different HAART agents, while also providing valuable insights into potential switching strategies and therapeutic options. The 4/7-day treatment option led to antiretroviral blood levels close to continuous treatment after the four consecutive days of medication, and to low levels at the end of the non-treatment period.
  • ||||||||||  Edurant (rilpivirine) / J&J, Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
    Journal:  Negative impact of a health insurer-mandated de-simplification from a single-tablet regimen to a two-tablet regimen. (Pubmed Central) -  Apr 10, 2024   
    A mandatory switch from an STR to a TTR in people with HIV proved unsuccessful, marked by low acceptance, and increased costs after one year. This underscores the necessity of incorporating patient and prescriber involvement in changing medication policies.
  • ||||||||||  Prezista (darunavir) / J&J, Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
    Journal:  Exploring Darunavir, Rilpivirine and Etravirine as Potential Therapies for Bladder Cancer: Efficacy and Synergistic Effects. (Pubmed Central) -  Mar 28, 2024   
    In summary, this pre-clinical investigation underscores the promising therapeutic potential of ETV and RPV, both as standalone treatments and in combination, hinting at repurposing opportunities in bladder cancer therapy, which could give a new treatment method for this disease that is faster and without as severe side effects as anticancer drugs. These findings represent a substantial stride in advancing personalized medicine within cancer research and will be further scrutinized in forthcoming studies.
  • ||||||||||  Vocabria (cabotegravir oral) / ViiV Healthcare
    Model-Based Comparison of Cabotegravir Pharmacokinetics Following Thigh and Gluteal Injections (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_951;    
    PPK modeling and simulation support chronic thigh administration of CAB LA QM and intermittent thigh injections for both QM and Q2M regimens. However, simulated chronic Q2M thigh administration did not maintain PK target established in pivotal trials and therefore is not recommended.
  • ||||||||||  First Trimester Exposure to Newer Antiretroviral Agents and Congenital Anomalies in a US Cohort (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_769;    
    The odds of congenital anomalies among infants with first trimester exposure to newer ARVs did not differ substantially from that among infants unexposed to these specific ARVs. However, modest effects cannot be ruled out, highlighting the need for continued evaluation of these associations in larger populations.
  • ||||||||||  Vocabria (cabotegravir oral) / ViiV Healthcare
    Cabotegravir PopPK Analysis of Adults & Adolescents Living With/At Risk for HIV Receiving PrEP (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_756;    
    P1/2, P2,
    The addition of adolescent data to the adult PopPK dataset allowed expansion of the prior PopPK model down to 35 kg and optimization of predictions in adolescents. Given the similarity of CAB PK across adolescents and adults, same dosing regimens apply for adults and adolescents.
  • ||||||||||  Estimated Costs of Eliminating Medicaid Prior Authorizations for Antiretrovirals in Washington State (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_544;    
    PrEP models assumed a 10% annual increase in the number of PrEP users and evaluated the impact of annual declines in the relative percentage of PrEP users on TDF/FTC with compensatory increases in TAF/FTC use; some models assumed the percentage of PrEP users on cabotegravir (CAB) would increase 1% annually...Our No PA Model assumed: 1) 18% annual relative increase in the percentage of PLWH on bictegravir/TAF/FTC; 2) the percentage of people on tenofovir/FTC taking TAF/FTC (vs. TDF/FTC) increases 9% annually; 3) CAB/rilpivirine increases 1% annually; 4) no change in darunavir/cobisistat; and 5) use of other ART drugs decline in proportion to their 2022 use...Elimination of Medicaid PAs will likely result in substantial new costs. Changes in drug formulary policy should consider opportunity costs.
  • ||||||||||  Antiretroviral Regimens Are Associated With Cognitive Function in People With HIV (Poster hall) -  Mar 5, 2024 - Abstract #CROI2024CROI_515;    
    Tenofovir (including TAF or TDF) and FTC were common in such regimens in combination with either DRV+COBI, RPV, or EFV. Our findings suggest complex associations between ART regimens and cognition, such that specific ART combinations rather than individual agents are associated with cognition.
  • ||||||||||  Edurant (rilpivirine) / J&J, Prezcobix (darunavir/cobicistat) / Gilead, J&J, dolutegravir/emtricitabine/tenofovir alafenamide (DTG/FTC/TAF) / Viatris
    Antiretroviral Concentrations in Post-Mortem Tissues: Preliminary Results From the Last Gift Program (Poster hall) -  Mar 5, 2024 - Abstract #CROI2024CROI_500;    
    This is the first study to report different ARV concentrations in different anatomical sites in humans. Previous studies on non-human primates showed similar results about the poor, but rather uniform, concentrations of DTG in all the districts of the CNS, and higher concentrations in kidney and intestine.
  • ||||||||||  efavirenz / Generic mfg.
    TDF and Efavirenz but Not InSTI or TAF Use Are Associated With Weight Gain During cART (Poster hall) -  Mar 5, 2024 - Abstract #CROI2024CROI_404;    
    Background: Combination antiretroviral therapy (cART) containing integrase strand transfer inhibitors (INSTIs) and/or tenofovir alafenamide (TAF) has been associated with greater weight gain (WG) than cART without these drugs...From 2008-2022 we studied all patients who initiated cART with either dolutegravir (DTG), bictegravir, elvitegravir, raltegravir, atazanavir, darunavir (DRV), rilpivirine (RIL), or efavirenz (EFV) as exclusive anchor drug if used in combination with either TAF, tenofovir disoproxil fumarate (TDF), or abacavir (ABC) as backbone...Over a 15-year period, our demographically diverse patient population experienced substantial WG in the first 3 years after cART initiation. Among 11 examined ARVs, only EFV and TDF were independently associated with (decreased) WG.
  • ||||||||||  Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare
    Phase I Study of Cabotegravir Long-Acting Injectable Formulations Supports ?4-Monthly Dose Interval () -  Mar 5, 2024 - Abstract #CROI2024CROI_213;    
    P1
    Safety and PK results from part A indicate low potential to achieve less frequent dosing with CAB200 and rHuPH20. The new CAB400 formulation (SC and IM) exhibits favorable safety and PK commensurate with dose intervals of ?4 months and is in ongoing clinical development.
  • ||||||||||  Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J
    Review, Journal:  Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine. (Pubmed Central) -  Dec 18, 2023   
    Practical guidance on the clinical management of CAB+RPV LA dosing, including a detailed discussion using case-based scenarios that may be encountered in clinical practice, is provided. The clinician-administered CAB+RPV LA regimen has dosing management considerations that are flexible and considerate of the patient and has the potential to provide a highly desirable and efficacious alternative to daily oral antiretroviral therapy for many people with HIV-1.
  • ||||||||||  efavirenz / Generic mfg.
    Journal, Adverse events:  Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects. (Pubmed Central) -  Dec 18, 2023   
    The clinician-administered CAB+RPV LA regimen has dosing management considerations that are flexible and considerate of the patient and has the potential to provide a highly desirable and efficacious alternative to daily oral antiretroviral therapy for many people with HIV-1. Higher levels of 8-OH-EFV were associated with CNS side effects, while EFV levels were only marginally associated with cognitive performance, thus suggesting that EFV and its metabolite may act differently in determining detrimental neurological effects.
  • ||||||||||  Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal, Real-world evidence, Real-world:  Cabotegravir (Pubmed Central) -  Nov 15, 2023   
    Tolerability of cabotegravir + rilpivirine LA intramuscular lateral thigh injections was similar to gluteal administration. In this large US cohort, most monthly CAB
  • ||||||||||  Journal:  GLP-1 agonists for people living with HIV and obesity, is there a potential? (Pubmed Central) -  Oct 22, 2023   
    Folate-decorated LNAs loading rilpivirine (RPV) were Theoretical considerations and a few available clinical observations support semaglutide and liraglutide prescription in people with HIV, with, thus far, no indications of concern regarding efficacy, safety or pharmacological interactions with ARVs.
  • ||||||||||  Significant sex differences in antiretroviral treatment of young HIV patients  (ePosters area) -  Oct 8, 2023 - Abstract #EACS2023EACS_1576;    
    INI: Overall, INI were used significantly more frequently in men (p<0.0001); especially, dolutegravir and bictegravir were used less frequently in women (p<0.0001)...The delayed use of newer HIV drugs might put young women at disadvantage in treatment. Our data support the ongoing call to action to enable pregnant women to participate in clinical trials and thus move from protection from research to protection through research.
  • ||||||||||  Intermittent three-drug regimens (i-3DR) as maintenance ART: a meta-analysis including individual participant data (ePosters) -  Oct 8, 2023 - Abstract #EACS2023EACS_462;    
    The breakdown of VF cases by antiretroviral class is depicted in the forest plot (Figure 1) for second generation (G) INSTI (Dolutegravir or Bictegravir, INSTI-2G); INSTI-1G (Raltegravir or Elvitegravir); NNRTI-1G (Efavirenz or Rilpivirine); NNRTI-2G (Etravirine or Doravirine) and boosted protease inhibitor (Darunavir, Lopinavir, Atazanavir) with significant heterogeneity overall (I-squared, 53%, p<0.01). Conclusions :